Next earnings date: 12 Aug 2025
Outlook Therapeutics, Inc. – NASDAQ:OTLK
Outlook Therapeutics stock price today
$2.69
+0.68
+33.83%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in 35 minutes
Outlook Therapeutics stock price monthly change
-77.11%
month
Outlook Therapeutics stock price quarterly change
-77.11%
quarter
Outlook Therapeutics stock price yearly change
+334.50%
year
Outlook Therapeutics key metrics
Market Cap | 33.47M |
Enterprise value | 220.56M |
P/E | -3.42 |
EV/Sales | N/A |
EV/EBITDA | -3.31 |
Price/Sales | N/A |
Price/Book | 15.29 |
PEG ratio | -0.29 |
EPS | -11.13 |
Revenue | N/A |
EBITDA | -60.65M |
Income | -154.60M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeOutlook Therapeutics stock price history
Outlook Therapeutics stock forecast
Outlook Therapeutics financial statements
| Mar 2023 | 0 | -6.65M | |
|---|---|---|---|
| Jun 2023 | 0 | -20.67M | |
| Sep 2023 | 0 | -12.99M | |
| Mar 2024 | 0 | -114.28M |
| Sep 2023 | 0 | -12.99M | |
|---|---|---|---|
| Mar 2024 | 0 | -114.28M | |
| Sep 2025 | 0 | -10.41M | |
| Oct 2025 | 3.05M | -6.27M | -205.87% |
Analysts Price target
Financials & Ratios estimates
| 2024-08-14 | -1.06 | -0.83 |
|---|
| Mar 2023 | 54024000 | 43.53M | 80.59% |
|---|---|---|---|
| Jun 2023 | 44447000 | 49.95M | 112.38% |
| Sep 2023 | 32300601 | 46.73M | 144.7% |
| Mar 2024 | 59028670 | 193.26M | 327.41% |
| Mar 2023 | -8.11M | 0 | -597.12K |
|---|---|---|---|
| Jun 2023 | -13.21M | 0 | 3.29M |
| Sep 2023 | -12.74M | 0 | 2.42M |
| Mar 2024 | -19.26M | 0 | 56.13M |
Outlook Therapeutics alternative data
| Aug 2023 | 17 |
|---|---|
| Sep 2023 | 17 |
| Oct 2023 | 17 |
| Nov 2023 | 17 |
| Dec 2023 | 17 |
| Jan 2024 | 24 |
| Feb 2024 | 24 |
| Mar 2024 | 24 |
| Apr 2024 | 24 |
| May 2024 | 24 |
| Jun 2024 | 24 |
| Jul 2024 | 24 |
Outlook Therapeutics other data
5.68%
-7.25%
of OTLK is owned by hedge funds
50
-25
12.92M
-14.50M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 64365 | 0 |
| Apr 2024 | 1785715 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | SYNTONE VENTURES LLC 10 percent owner | Common Stock | 714,286 | $7 | $5,000,002 | ||
Purchase | SYNTONE VENTURES LLC 10 percent owner | Warrant (Right to Buy) | 1,071,429 | $7.7 | $8,250,003 | ||
Purchase | HADDADIN YEZAN MUNTHER director | Common Stock | 1,881 | $11.82 | $22,233 | ||
Purchase | EVANSON JEFF officer: CHIEF COMMERCIAL OFFICER | Common Stock | 62,484 | $0.42 | $26,243 | ||
Sale | DAGNON TERRY officer: Chief Op.. | Common Stock | 520,000 | $1.14 | $590,200 | ||
Sale | EVANSON JEFF officer: Chief Commercial Officer | Common Stock | 267,000 | $1.11 | $296,370 | ||
Sale | EVANSON JEFF officer: Chief Commercial Officer | Common Stock | 103,255 | $1.22 | $125,971 | ||
Sale | EVANSON JEFF officer: Chief Commercial Officer | Common Stock | 33,738 | $1.25 | $42,173 | ||
Sale | EVANSON JEFF officer: Chief Commercial Officer | Common Stock | 27,162 | $1.31 | $35,582 | ||
Purchase | SUKHTIAN FAISAL GHIATH director | Common Stock | 30,000 | $1.29 | $38,700 |
| Patent |
|---|
Application Filling date: 17 Apr 2019 Issue date: 29 Jul 2021 |
Grant Filling date: 21 Jan 2016 Issue date: 30 Jun 2020 |
Grant Filling date: 16 Oct 2014 Issue date: 13 Aug 2019 |
| Quarter | Transcript |
|---|---|
| Q2 2024 16 May 2024 | Q2 2024 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Lawrence A. Kenyon CPA (1966) Chief Financial Officer, Treasurer, Company Sec. & Director | $562,880 |
Mr. Jeffrey Evanson (1969) Chief Commercial Officer | $159,680 |
| Mr. Terry Dagnon (1962) Chief Operating Officer | $159,680 |
Outlook Therapeutics: Speculative Buy With High Stakes In The Anti-VEGF Market
Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval
Outlook Therapeutics: August PDUFA For Wet AMD Blockbuster
Outlook Therapeutics: A One-Buck Lottery Ticket
Outlook Therapeutics: Likely FDA Approval, Possible Buyout
-
What's the price of Outlook Therapeutics stock today?
One share of Outlook Therapeutics stock can currently be purchased for approximately $2.69.
-
When is Outlook Therapeutics's next earnings date?
Outlook Therapeutics, Inc. is estimated to report earnings on Tuesday, 12 Aug 2025.
-
Does Outlook Therapeutics pay dividends?
No, Outlook Therapeutics does not pay dividends.
-
How much money does Outlook Therapeutics make?
Outlook Therapeutics has a market capitalization of 33.47M. Outlook Therapeutics made a loss 75.37T US dollars in net income (profit) last year or -$0.83 on an earnings per share basis.
-
What is Outlook Therapeutics's stock symbol?
Outlook Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "OTLK".
-
What is Outlook Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Outlook Therapeutics?
Shares of Outlook Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Outlook Therapeutics's key executives?
Outlook Therapeutics's management team includes the following people:
- Mr. Lawrence A. Kenyon CPA Chief Financial Officer, Treasurer, Company Sec. & Director(age: 59, pay: $562,880)
- Mr. Jeffrey Evanson Chief Commercial Officer(age: 56, pay: $159,680)
- Mr. Terry Dagnon Chief Operating Officer(age: 63, pay: $159,680)
-
How many employees does Outlook Therapeutics have?
As Jul 2024, Outlook Therapeutics employs 24 workers.
-
When Outlook Therapeutics went public?
Outlook Therapeutics, Inc. is publicly traded company for more then 9 years since IPO on 14 Jun 2016.
-
What is Outlook Therapeutics's official website?
The official website for Outlook Therapeutics is outlooktherapeutics.com.
-
Where are Outlook Therapeutics's headquarters?
Outlook Therapeutics is headquartered at Building F, Iselin, NJ.
-
How can i contact Outlook Therapeutics?
Outlook Therapeutics's mailing address is Building F, Iselin, NJ and company can be reached via phone at +60 9 619 3990.
Outlook Therapeutics company profile:
Outlook Therapeutics, Inc.
outlooktherapeutics.comExchange:
NASDAQ
Full time employees:
24
Industry:
Biotechnology
Sector:
Healthcare
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Building F
Iselin, NJ 08852
Iselin, NJ 08852
CIK: 0001649989
ISIN: US69012T3059
CUSIP: 69012T206
